Zhou, Jian-Guo http://orcid.org/0000-0002-5021-3739
Zhou, Nan-Jing
Zhang, Qiong
Feng, Yao-yao
Zhou, Hang http://orcid.org/0000-0001-9089-4527
Funding for this research was provided by:
Special Fund for Traditional Chinese Medicine and Ethnic Medicine (No.QZYY2017-113)
Zunyi Medical University Training Program of Innovation and Entrepreneurship for Undergraduates (ZY-201751044)
Zunyi Medical University School of medicine and Science Training Program of Innovation and Entrepreneurship for Undergraduates (ZYKY-20173830)
the Master Scientific Research Foundation of Zunyi Medical University.
the Open Project Program of the Special Key Laboratory of Oral Diseases Research, Higher Education Institution in Guizhou Province
Article History
Received: 11 February 2018
Accepted: 12 August 2018
First Online: 17 September 2018
Ethics approval and consent to participate
: This clinical trial will be undertaken strictly according to the protocol and GCP regulations. Ethics approval has been granted by the institutional ethical review board of the Affiliated Hospital of Zunyi Medical College (2017–01).
: Our findings will be reported in peer-reviewed publications, conference presentations, and policy forums. They will provide detailed information on the use and outcomes of apatinib for advanced or recurrent cervical cancer.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.